Food and Drug Administration Drug Safety Podcast
FDA Drug Safety Podcast: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue
- Author: Podcast
- Narrator: Podcast
- Publisher: Podcast
- Duration: 0:03:00
- More information
Informações:
Synopsis
Listen to an audio podcast of the May 22, 2017 FDA Drug Safety Communication. FDA announced that to date a review has not identified adverse health effects from gadolinium retained in the brain after the use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI); review to
